Leerink Partnrs Has Positive Outlook of TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Leerink Partnrs upped their FY2026 earnings per share estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.52 for the year, up from their previous estimate of $0.51. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $60.87 million. During the same quarter last year, the business earned ($1.17) earnings per share. The firm’s quarterly revenue was up 69.6% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on TVTX. Piper Sandler raised their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Canaccord Genuity Group reduced their price target on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Cantor Fitzgerald began coverage on Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating for the company. Scotiabank raised their target price on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Finally, Wedbush upped their price target on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $19.46 on Tuesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -4.28 and a beta of 0.70. The company has a 50 day moving average of $18.23 and a 200-day moving average of $14.75. Travere Therapeutics has a one year low of $5.12 and a one year high of $20.33.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors have recently modified their holdings of TVTX. Millennium Management LLC grew its holdings in Travere Therapeutics by 33.9% during the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after acquiring an additional 747,406 shares during the period. Emerald Advisers LLC grew its stake in Travere Therapeutics by 19.8% during the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after purchasing an additional 323,513 shares during the period. Finepoint Capital LP grew its stake in Travere Therapeutics by 0.3% during the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after purchasing an additional 5,539 shares during the period. Geode Capital Management LLC increased its holdings in Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after purchasing an additional 64,744 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its stake in Travere Therapeutics by 26.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after buying an additional 244,444 shares during the period.

Insider Transactions at Travere Therapeutics

In other news, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the transaction, the insider now owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the sale, the chief accounting officer now directly owns 54,927 shares in the company, valued at $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,596 shares of company stock valued at $527,262. 4.06% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.